NCT03638375 2023-12-12
ACTME
Leiden University Medical Center
Phase 1/2 Unknown
Clinical Trials
23 trialsNCT04981899 2023-04-12
NICE-40
St. Petersburg State Pavlov Medical University
Phase 1/2 Unknown
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT03995017 2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2 Unknown
NCT03682276 2022-12-13
PRIME-HCC
Imperial College London
Phase 1/2 Unknown
NCT05027204 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT05468294 2022-07-21
Nivokin
Philogen S.p.A.
Phase 1/2 Unknown
NCT05265650 2022-07-19
Noelia
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown
NCT03374839 2022-05-06
Nivo-TIL
Nantes University Hospital
Phase 1/2 Unknown
NCT03161756 2022-04-07
CHARLI
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Unknown
NCT05236608 2022-03-25
ADIVO Lung
National University Hospital, Singapore
Phase 1/2 Unknown
NCT05162118 2022-03-09
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
Zhejiang University
Phase 1/2 Unknown
NCT04233840 2022-01-27
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma
National Taiwan University Hospital
Phase 1/2 Unknown
NCT04620954 2021-12-01
ORION-02
National Cancer Centre, Singapore
Phase 1/2 Unknown
NCT02948348 2021-09-16
Study to Nivolumab Following Preoperative Chemoradiotherapy
National Cancer Center Hospital East
Phase 1/2 Unknown
NCT04061863 2021-09-08
KORNELIA
Seoul National University Hospital
Phase 1/2 Unknown
NCT04521075 2021-08-16
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Ella Therapeutics Ltd
Phase 1/2 Unknown
NCT02913417 2021-04-19
Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases
California Pacific Medical Center Research Institute
Phase 1/2 Unknown
NCT04021420 2020-08-20
SONIMEL01
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Unknown
NCT03993626 2019-06-21
CAROSELL
Celleron Therapeutics Ltd.
Phase 1/2 Unknown
NCT03792724 2019-01-03
INTRUST
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown